Press Releases Resverlogix Corp.

Equities

RVX

CA76128M1086

Market Closed - Toronto S.E. Other stock markets 12:07:16 2024-04-29 pm EDT			5-day change	1st Jan Change
0.055 ^CAD	-8.33%		0.00%	-21.43%

Apr. 01	Resverlogix Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Feb. 21	Resverlogix Corp. Announces Resignation of Shawn Lu from the Board of Directors	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Resverlogix Announces Change to Its Board of Directors	Feb. 21	NE
Resverlogix Announces Publication of its 40th Scientific Journal Article on Apabetalone's Potential Therapeutic Benefits	Jan. 11	NE
Resverlogix Publishes on Apabetalone's Potential for the Treatment of FSHD, the Third Most Common Muscular Dystrophy	23-10-04	NE
RESVERLOGIX ANNOUNCES A FAVORABLE OUTLOOK BASED ON NEW CARDIOVASCULAR DISEASE TREATMENT GUIDELINES FOR PATIENTS WITH TYPE 2 DIABETES	23-08-30	AQ
Resverlogix : Financial Statement Q2 2023	23-08-12	PU
RESVERLOGIX ANNOUNCES WARRANT REPRICING AND ONE-YEAR EXTENSION	23-06-30	AQ
RESVERLOGIX ANNOUNCES NEW INSIGHTS INTO THE MECHANISM OF APABETALONE'S CARDIOPROTECTIVE BENEFIT IN CHRONIC KIDNEY DISEASE PATIENTS	23-06-13	AQ
Resverlogix : Financial Statement Q1 2023	23-05-11	PU
Resverlogix : MD&A Q1 2023	23-05-11	PU
Resverlogix : Annual Meeting of Shareholders - Notice of Meeting and Management Information Circular	23-05-09	PU
Resverlogix : Annual Information Form 2022	23-03-31	PU
Resverlogix : Financial Statement Q4 2022	23-03-31	PU
Resverlogix : MD&A Q4 2022	23-03-31	PU
Resverlogix : Annual Information Form 2021	23-03-31	PU
RESVERLOGIX ANNOUNCES ONE-YEAR EXTENSION OF DEBENTURE	23-03-21	AQ
Resverlogix : Financial Statement Q3 2022	22-11-11	PU
Resverlogix Confirms Focus on Treatment of Post COVID-19 Conditions	22-09-28	GL
Resverlogix Confirms Focus on Treatment of Post COVID-19 Conditions	22-09-28	AQ
Resverlogix Publishes New Data Highlighting Apabetalone’s Benefit in Non-alcoholic Fatty Liver Disease	22-08-22	GL
Resverlogix Publishes New Data Highlighting Apabetalone’s Benefit in Non-alcoholic Fatty Liver Disease	22-08-22	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Resverlogix Corp.

Equities

RVX

CA76128M1086

Press Releases

Filters